


WAY-100635

Cat. No.:	HY-10349		
CAS No.:	162760-96-5		
Molecular Formula:	C ₂₅ H ₃₄ N ₄ O ₂		
Molecular Weight:	422.56		
Target:	5-HT Receptor; Dopamine Receptor		
Pathway:	GPCR/G Protein; Neuronal Signaling		
Storage:	Pure form	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 66.67 mg/mL (157.78 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM		2.3665 mL	11.8326 mL	23.6653 mL
		5 mM		0.4733 mL	2.3665 mL	4.7331 mL
10 mM			0.2367 mL	1.1833 mL	2.3665 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.92 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.92 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.92 mM); Clear solution 					

BIOLOGICAL ACTIVITY

Description	WAY-100635 is a potent and selective 5-HT _{1A} Receptor antagonist with a pIC ₅₀ of 8.87, an apparent pA ₂ of 9.71. WAY-100635 is a potent and selective 5-hydroxytryptamine 1A (5-HT _{1A}) receptor antagonist with an IC ₅₀ value of 0.91 nM and K _i value of 0.39 nM. WAY-100635 has pIC ₅₀ values for 5-HT _{1A} and α ₁ -adrenergic receptors of 8.9 and 6.6, respectively. WAY-100635 is also a potent dopamine D ₄ receptor agonist ^{[1][2][3]} .		
IC₅₀ & Target	D ₄ Receptor	5-HT _{1A} Receptor 8.87 (pIC ₅₀)	5-HT _{1A} Receptor 9.71 (pA ₂)

In Vitro	<p>The functional properties and binding affinities of WAY-100635 are evaluated in HEK 293 cells stably expressing dopamine D_{2L} or D_{4,4} receptors^[1].</p> <p>WAY-100635 displays 940, 370, and 16 nM binding affinities at D_{2L}, D₃, and D_{4,2} receptors, respectively. Saturation analyses demonstrate that the K_d of [³H] WAY-100635 at D_{4,2} receptors is 2.4 nM. WAY-100635 is potent agonist in HEK-D_{4,4} cells with EC₅₀ of 9.7 nM. WAY-100635 possesses high affinity for D_{4,4} receptor (3.3 nM) ^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>WAY-100635 (1 mg/kg; subcutaneous injection; male Sprague-Dawley rats) treatment abolishes the reduction of the severity of abstinence signs induced by <i>Rhodiola rosea</i> administration in nicotine-dependent rat^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" data-bbox="345 485 1515 751"> <tr> <td data-bbox="345 485 617 548">Animal Model:</td> <td data-bbox="617 485 1515 548">Male Sprague-Dawley rats (220-240 g)^[2]</td> </tr> <tr> <td data-bbox="345 548 617 611">Dosage:</td> <td data-bbox="617 548 1515 611">1 mg/kg</td> </tr> <tr> <td data-bbox="345 611 617 674">Administration:</td> <td data-bbox="617 611 1515 674">Subcutaneous injection (Pharmacokinetic study)</td> </tr> <tr> <td data-bbox="345 674 617 751">Result:</td> <td data-bbox="617 674 1515 751">Reduced total abstinence score, increased immobility time and the burying behavior was increased.</td> </tr> </table>	Animal Model:	Male Sprague-Dawley rats (220-240 g) ^[2]	Dosage:	1 mg/kg	Administration:	Subcutaneous injection (Pharmacokinetic study)	Result:	Reduced total abstinence score, increased immobility time and the burying behavior was increased.
Animal Model:	Male Sprague-Dawley rats (220-240 g) ^[2]								
Dosage:	1 mg/kg								
Administration:	Subcutaneous injection (Pharmacokinetic study)								
Result:	Reduced total abstinence score, increased immobility time and the burying behavior was increased.								

CUSTOMER VALIDATION

- Nat Neurosci. 2021 Dec 9.
- Psychopharmacology. 2022 Sep 15.
- Chin J Integr Med. 2019 Nov 29.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Chemel BR, et al. WAY-100635 is a potent dopamine D4 receptor agonist. *Psychopharmacology (Berl)*. 2006 Oct;188(2):244-51.
- [2]. Mannucci C, et al. Serotonin involvement in *Rhodiola rosea* attenuation of nicotine withdrawal signs in rats. *Phytomedicine*. 2012 Sep 15;19(12):1117-24.
- [3]. Al Hussainy R, et al. Design, synthesis, radiolabeling, and in vitro and in vivo evaluation of bridgehead iodinated analogues of N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) as potential SPECT ligands for the 5-HT1A receptor. *J Med Chem*. 2011 May 26;54(10):3480-91.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA